1. Home
  2. TXG vs ZYME Comparison

TXG vs ZYME Comparison

Compare TXG & ZYME Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo 10x Genomics Inc.

TXG

10x Genomics Inc.

HOLD

Current Price

$21.69

Market Cap

2.3B

Sector

Industrials

ML Signal

HOLD

Logo Zymeworks Inc.

ZYME

Zymeworks Inc.

HOLD

Current Price

$26.76

Market Cap

1.9B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
TXG
ZYME
Founded
2012
2003
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Laboratory Analytical Instruments
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.3B
1.9B
IPO Year
2019
2022

Fundamental Metrics

Financial Performance
Metric
TXG
ZYME
Price
$21.69
$26.76
Analyst Decision
Hold
Strong Buy
Analyst Count
15
11
Target Price
$20.25
$38.90
AVG Volume (30 Days)
2.4M
517.9K
Earning Date
05-07-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
76.97
33.33
EPS
N/A
N/A
Revenue
$245,893,000.00
$105,965,000.00
Revenue This Year
N/A
$183.10
Revenue Next Year
$7.33
N/A
P/E Ratio
N/A
N/A
Revenue Growth
68.06
38.87
52 Week Low
$7.72
$10.89
52 Week High
$26.45
$29.75

Technical Indicators

Market Signals
Indicator
TXG
ZYME
Relative Strength Index (RSI) 47.90 49.47
Support Level $11.66 $22.28
Resistance Level $23.43 $27.35
Average True Range (ATR) 1.42 1.03
MACD -0.32 -0.23
Stochastic Oscillator 31.02 11.52

Price Performance

Historical Comparison
TXG
ZYME

About TXG 10x Genomics Inc.

10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The company's integrated solutions include instruments, consumables, and software for analyzing biological systems at a resolution and scale that matches the complexity of biology. Its product offerings include a Chromium platform comprising microfluidic chips and related consumables, Chromium X series, Visium and Xenium platforms, and others, which are predominantly used for the study of biological components. Geographically, the company derives operates from the United States and the rest from Americas (excluding the United States), Europe, Middle East and Africa, China, and Asia-Pacific (excluding China).

About ZYME Zymeworks Inc.

Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enables precise engineering of differentiated therapeutic product candidates. Its clinical candidate, zanidatamab, is a novel HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. It is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.

Share on Social Networks: